Patents by Inventor Nigel Crutchley

Nigel Crutchley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11744799
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 5, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou
  • Publication number: 20230226077
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Application
    Filed: March 20, 2023
    Publication date: July 20, 2023
    Applicant: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
  • Patent number: 11696919
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 11, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
  • Patent number: 11638711
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: May 2, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
  • Patent number: 11458125
    Abstract: The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 4, 2022
    Assignee: MC2 Therapeutics Limited
    Inventor: Nigel Crutchley
  • Publication number: 20220273627
    Abstract: The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 1, 2022
    Applicant: MC2 Therapeutics Limited
    Inventor: Nigel CRUTCHLEY
  • Publication number: 20220110868
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.
    Type: Application
    Filed: January 30, 2018
    Publication date: April 14, 2022
    Inventors: Nigel CRUTCHLEY, Michelle GEORGIOU
  • Publication number: 20210275554
    Abstract: The present invention relates to a composition for topical application comprising a continuous aqueous phase, a discontinuous liquid oil phase, and crisaborole.
    Type: Application
    Filed: July 31, 2018
    Publication date: September 9, 2021
    Applicant: MC2 Therapeutics Limited
    Inventor: Nigel CRUTCHLEY
  • Publication number: 20210015831
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 21, 2021
    Applicant: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
  • Publication number: 20190060288
    Abstract: The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.
    Type: Application
    Filed: April 3, 2017
    Publication date: February 28, 2019
    Inventor: Nigel CRUTCHLEY
  • Patent number: 9549896
    Abstract: A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: January 24, 2017
    Assignee: DRUG DELIVERY SOLUTIONS LIMITED
    Inventors: Nigel Crutchley, Steen Sindet-Pedersen, Stephen Lenon
  • Publication number: 20100189770
    Abstract: A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent.
    Type: Application
    Filed: June 26, 2008
    Publication date: July 29, 2010
    Inventors: Nigel Crutchley, Steen Sindet-Pedersen, Stephen Lenon
  • Publication number: 20070071684
    Abstract: A method of coating the surface of a substrate which comprises the steps of: i) contacting the surface with a polymerisable mixture comprising one or more polymerisable components and containing suspended droplets of a biliquid foam or of a high internal oil phase emulsion, the said droplets being stabilised by a non-reactive surfactant; and ii) polymerising the coating to form a polymer comprising the droplets entrapped therein.
    Type: Application
    Filed: September 23, 2004
    Publication date: March 29, 2007
    Inventors: Nigel Crutchley, James Guthrie, Derek Wheeler, Stephen Lenon
  • Publication number: 20050238676
    Abstract: A discrete powder which comprises particles in which a biliquid foam has been entrapped with a matrix of a polymeric material. A process for the preparation of these discrete powders comprises the steps of: i) preparing a biliquid foam, ii) forming a dispersion of the biliquid foam in an aqueous solution, suspension or dispersion of a polymeric material, and iii) subjecting the dispersion to drying under conditions such that a discrete powder is formed.
    Type: Application
    Filed: June 24, 2003
    Publication date: October 27, 2005
    Inventors: David Charles Gladman, Stephen Lenon, Nigel Crutchley